Korean J Hematol 2007; 42(4):
Published online December 30, 2007
https://doi.org/10.5045/kjh.2007.42.4.301
© The Korean Society of Hematology
정기주, 강명수, 권기두, 김경하, 이종찬, 이상철, 김현정, 배상병, 김찬규, 이남수, 이규택, 박성규, 원종호, 홍대식, 박희숙
순천향대학교 의과대학 내과학교실, 종양혈액내과학교실
Background:
Autologous peripheral hematopoietic stem cell transplantation (APBSCT) has been widely used to treat various types of hematological disorders, metabolic diseases and congenital immunodeficiency. Hematopoietic recovery is important because prolonged duration of neutropenia and thrombocytopenia is associated with a higher risk of infection, bleeding and treatment related mortality. Many investigators have studied the factors that affect hematopoietic recovery after stem cell transplantation.
Methods:
We retrospectively investigated the factors influencing hematopoietic engraftment in 112 patients with hematological malignancies and solid tumors who received APBSCT. We evaluated the gender, age, CD34+ cell number, conditioning regimens, and the type of tumor and their association with neutrophil and platelet engraftment.
Results:
Post-transplant neutrophil engraftment (>500/ՌL) required a median of 11 days (range 6∼50) and platelet engraftment 12 (range 1∼78) days (>20,000/ՌL). The univariate analysis showed that the factors that positively affected hematopoietic recovery were: the type of conditioning regimens such as BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) and BEAC (BCNU, etoposide, cytosine arabinoside, cyclophosphamide) versus BC (busulfan, cyclophosphamide), the CD34+ cell number and the disease diagnosis such as multiple myeloma versus acute myelogenous leukemia. The multivariate analysis showed only the CD34+cell number (5∼10×106/kg) to be significantly associated with early neutrophil and platelet engraftment (P<.001).
Conclusion:
These findings suggest that measurement of the CD34+ cell count may be sufficient to predict the time to engraftment after APBSCT.
Keywords Engraftment, Autologous, Stem cell transplantation
Korean J Hematol 2007; 42(4): 301-308
Published online December 30, 2007 https://doi.org/10.5045/kjh.2007.42.4.301
Copyright © The Korean Society of Hematology.
정기주, 강명수, 권기두, 김경하, 이종찬, 이상철, 김현정, 배상병, 김찬규, 이남수, 이규택, 박성규, 원종호, 홍대식, 박희숙
순천향대학교 의과대학 내과학교실, 종양혈액내과학교실
Ki Ju Jeung, Myung Soo Kang, Ki Du Kwon, Kyoung Ha Kim, Jong Chan Lee, Sang Chul Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taeg Lee, Sung Kyu Park, Jong Ho Won, Dae Sik Hong, Hee Sook Park
Department of Internal Medicine and, Division of Hematology and Oncology, Soonchunhyang University College of Medicine, Bucheon, Korea
Background:
Autologous peripheral hematopoietic stem cell transplantation (APBSCT) has been widely used to treat various types of hematological disorders, metabolic diseases and congenital immunodeficiency. Hematopoietic recovery is important because prolonged duration of neutropenia and thrombocytopenia is associated with a higher risk of infection, bleeding and treatment related mortality. Many investigators have studied the factors that affect hematopoietic recovery after stem cell transplantation.
Methods:
We retrospectively investigated the factors influencing hematopoietic engraftment in 112 patients with hematological malignancies and solid tumors who received APBSCT. We evaluated the gender, age, CD34+ cell number, conditioning regimens, and the type of tumor and their association with neutrophil and platelet engraftment.
Results:
Post-transplant neutrophil engraftment (>500/ՌL) required a median of 11 days (range 6∼50) and platelet engraftment 12 (range 1∼78) days (>20,000/ՌL). The univariate analysis showed that the factors that positively affected hematopoietic recovery were: the type of conditioning regimens such as BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) and BEAC (BCNU, etoposide, cytosine arabinoside, cyclophosphamide) versus BC (busulfan, cyclophosphamide), the CD34+ cell number and the disease diagnosis such as multiple myeloma versus acute myelogenous leukemia. The multivariate analysis showed only the CD34+cell number (5∼10×106/kg) to be significantly associated with early neutrophil and platelet engraftment (P<.001).
Conclusion:
These findings suggest that measurement of the CD34+ cell count may be sufficient to predict the time to engraftment after APBSCT.
Keywords: Engraftment, Autologous, Stem cell transplantation
Gi-June Min, Byung-Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hawn Shin, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
Blood Res 2022; 57(3): 197-206Ryul Kim, Youngil Koh, Dong-Yeop Shin, Pyoeng Gyun Choe, Nam Joong Kim, Sung-soo Yoon, Myoung-don Oh, Wan Beom Park, and Inho Kim
Blood Res 2017; 52(4): 300-306Il-Young Jang, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Kwang-Kuk Kim, Young-Min Lim, Won-Ki Min, and Cheolwon Suh
Blood Res 2014; 49(1): 42-48